Home › Chronic Lymphocytic Leukemia › Nevada
Chronic Lymphocytic Leukemia clinical trials in Nevada
6 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Nevada.
Cities in Nevada
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Optum Medical Group (Rhodes) P.C., Las Vegas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07342478A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 5434), Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05947851A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Comprehensive Cancer Centers of Nevada, Henderson
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06588478Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- and 24 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Comprehensive Cancer Centers of Nevada, Las Vegas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07520006A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Comprehensive Cancer Centers of Nevada, Las Vegas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.